CWS yields 0.33% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, CWS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CWS + ABBV for your $10,000?
Complement to any Broad-Based Index Fund — CWS’s strategy seeks to avoid the fundamentally weak companies that index-based funds generally hold and only invest in those perceived as “first in class” firms. Low Turnover — CWS’s strategy is focused on the long term. That’s why CWS aims for a buy-and-hold strategy, trading as infrequently as possible and holding for as long as it can. CWS believes that a disciplined buy-and-hold strategy is ideal for riding out market storms. Innovative Fulcrum Fee Structure — CWS’s Portfolio Strategist’s manager fee is directly tied to performance: outperformance is rewarded with a larger management fee; underperformance is penalized with a smaller management fee. Disciplined Alpha Seeking Strategy — CWS is focused on a core group of what we believe are outstanding firms, offering investors a simple way to get instant exposure to a concentrated equity portfolio of companies with proven competitive advantages.
Full CWS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.